Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study

Ikegame, Kazuhiro; Kaida, Katsuji; Fukunaga, Kohji; Osugi, Yuko; Yoshihara, Kyoko; Yoshihara, Satoshi; Ishii, Shin‐ichi; Fujino, Satoshi; Yamashita, T.; Mayumi, Azusa; Maruyama, Satoshi; Teramoto, Masaaki; Inoue, Takayuki; Okada, Masaya; Tamaki, Hiroya; Ogawa, Hiroyasu; Fujimori, Y

doi:10.1038/s41409-020-0980-8

Cited by 4 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over recent decades, great progress has been made in haplo-HSCT for hematological malignant disease due to the advent of novel conditioning regimens, optimized draft manipulation, improved GVHD prophylaxis, and advances in supportive care. A prospective study on HLA haplotype-mismatched family donor HSCT to treat hematological disease showed that donor chimerism was more rapidly achieved in patients who underwent HLA haploidentical-matched family donor HSCT than in those who underwent HLA-matched HSCT 12 . Some studies also thought that the matching degree of HLA (6/6 and 4/6 or 5/6) had no influence on implantation and survival time after the second transplantation using umbilical cord blood 13 .…”

Section: Discussionmentioning

confidence: 99%

Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia

Gui

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Severe aplastic anemia (SAA) is a life-threatening hematological disorder. The major therapies include matched sibling donor (MSD)- hematopoietic stem cell transplantation (HSCT), matched unrelated donor (MUD)-HSCT and immunosuppressive therapy (IST). However, there are many problems that can occur after HSCT, and graft failure (GF) is one of the most serious complications. To find an effective treatment, we analyzed 10 cases of second HSCT to treat SAA pediatric patients who suffered from GF and concluded that second haploidentical family donors HSCT is an effective treatment. Moreover, adding a small dose of busulfan or 2 ~ 3 Gy total body irradiation (TBI) in nonmyeloablative regimens (NMAs) can promote the engraftment. Although the study also showed that PBSCs, as a source of stem cells, can promote the implantation of neutrophil cells, due to small sample size, more research is still needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia

Gui

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

Donor-derived cytomegalovirus-specific CD8+ T cells restricted to shared, donor-specific, or host-specific HLA after HLA mismatched hematopoietic stem cell transplantation

Ikegame,

Fukunaga,

Osugi

et al. 2024

Transplant Immunology

View full text Add to dashboard Cite

Plasma Exchange for Transplantation-Associated Thrombotic Microangiopathy in Stem Cell Transplantation From an Hla-Mismatched Family Donor

Kitagawa

Fukunaga

Oshima

et al. 2023

JJTC

View full text Add to dashboard Cite

Objective: HLA-mismatched stem cell transplantation (SCT) from a family donor using steroids for graft-versus-host disease (GVHD) prophylaxis is useful in refractory hematological diseases, but is associated with many complications.The purpose of this study was to investigate the efficacy of plasma exchange (PE) therapy for transplantationassociated thrombotic microangiopathy (TA-TMA) in patients with HLA-mismatched SCT. Methods: Between October 2016 and September 2021, we retrospectively evaluated 22 patients who developed TA-TMA and received PE after HLA-mismatched SCT from a family donor. Results: Median age was 36 years. Twenty-one patients were in a state of non-remission, and 4 patients had a 2-HLA-haplotype mismatched family donor. For GVHD prophylaxis, tacrolimus plus methylprednisolone was administered to all patients. PE was effective in 15 patients (68.2%), and duration from the onset of TA-TMA to PE initiation was slightly shorter in these cases. Three patients developed heart failure during PE, although this was reversible. The 100-day and 1-year survival rates were 50.0% and 9.1%, respectively. Conclusion: PE may be effective and safe for TA-TMA after allogeneic HLA-mismatched SCT.

show abstract

Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study

Cited by 4 publications

References 58 publications

Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia

Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia

Donor-derived cytomegalovirus-specific CD8+ T cells restricted to shared, donor-specific, or host-specific HLA after HLA mismatched hematopoietic stem cell transplantation

Plasma Exchange for Transplantation-Associated Thrombotic Microangiopathy in Stem Cell Transplantation From an Hla-Mismatched Family Donor

Contact Info

Product

Resources

About